Skip to main content

Table 3 Estimated likelihood ratios for predicting BRCA1 or BRCA2 mutation status defined by breast tumor triple-negative phenotype

From: Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

Gene

Breast tumor phenotype

Diagnosis <50 years

Diagnosis ≥50 to 70 years

% Carriers

% BCAC

LR

(95% CI)

% Carriers

% BCAC

LR

(95% CI)

BRCA1

Triple-negative

67.3

17.5

3.73

(3.43-4.05)

57.7

12.9

4.41

(3.86-5.04)

Not triple-negative

32.7

82.5

0.40

(0.37-0.44)

42.3

87.1

0.49

(0.42-0.56)

 

100%

100%

  

100%

100%

  

BRCA2

Triple-negative

13.0

17.5

0.72

(0.59-0.87)

23.5

12.9

1.79

(1.42-2.24)

Not triple-negative

87.0

82.5

1.06

(0.98-1.15)

76.5

87.1

0.88

(0.78-1.00)

 

100%

100%

  

100%

100%

  
  1. Analyses stratified by country, as described in the Methods section. Analysis included tumor phenotypes from 2,249 BRCA1 mutation carriers (1,788 < 50 years, 461 ≥ 50 years), 1,195 BRCA2 mutation carriers (859 < 50 years, 336 ≥ 50 years) and 19,178 BCAC cases with no report of positive BRCA1/2 mutation status (7,103 < 50 years, 12,075 ≥ 50 years). LR, likelihood ratio. Triple-negative phenotype defined as ER-negative, PR-negative, HER2-negative; not triple-negative; all other combinations, with status measured for all three markers.